Several countries have recently approved the use of cannabis flowering tops with standardized amount of Δ9-tetrahydrocannabinol (Δ9-THC), cannabidiol (CBD) for the treatment of different diseases. Therapeutic monitoring of medical cannabis products administered to patients for the established pathologies is rarely carried out.
Methods: the aim of this study is to develope, and fully validate an ultra-high-performance liquid chromatography-tandem mass spectrometry method to quantify Δ9-THC, CBD, and metabolites, i.e., 11-nor-9-carboxy-THC (THC-COOH), 11-hydroxy-THC (11-OH-THC) cannabidiol-7-oic acid (7-COOH-CBD), 7-hydroxycannabidiol (7-OH-CBD), 6-α-hydroxycannabidiol (6-α-OH-CBD) and 6-β-hydroxycannabidiol (6-β-OH-CBD) in hair samples of patients treated with medical cannabis.
Alfredo Fabrizio Lo Faro1, Diletta Berardinelli 1, Massimo Mario Di Muzio 1, Paolo Berretta 2, Anastasio Tini 1
1.Department of Excellence-Biomedical Sciences and Public Health, Università Politecnica delle Marche, 60121 Ancona, Italy 2 Department of Clinical Pharmacy-Institute INRCA-IRCCS – Ancona, Italy
2.National Centre on Addiction and Doping, Istituto Superiore di Sanità, 00161 Rome, Italy
Maggiori informazioni sono disponibili sul sito fonte: SIBIOC